Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 7, 2008, Pages 812-819

  Kobayashi, Hironori ^a   Miura, Tetsuji ^a   Ishida, Hideyuki ^b   Miki, Takayuki ^a   Tanno, Masaya ^a   Yano, Toshiyuki ^a   Sato, Takahiro ^a   Hotta, Hiroyuki ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium overload; Erythropoietin; Infarct size; Mitochondria; Signal transduction

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENINE NUCLEOTIDE TRANSLOCASE; CALCIUM; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OUABAIN; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CELL ISOLATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; MUSCLE CONTRACTURE; NONHUMAN; PROTEIN INTERACTION; RABBIT; REPERFUSION; REPERFUSION INJURY;

ANIMALS; ERYTHROPOIETIN; MALE; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS;

EID: 44249103783     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04925.x     Document Type: Article

References (33)

1. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005 293 : 90 5.
2. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res. Cardiol. 2005 100 : 397 403.
3. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury. Role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 2005 19 : 1323 5.
4. Hirata A, Minamino T, Asanuma H et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 2006 48 : 176 84.
5. Hirata A, Minamino T, Asanuma H et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc. Drugs Ther. 2005 19 : 33 40.
6. Lipsic E, van der Meer P, Henning RH et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. 2004 44 : 473 9.
7. Miki T, Miura T, Yano T et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J. Pharmacol. Exp. Ther. 2006 317 : 68 75.
8. Nishihara M, Miura T, Miki T et al. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am. J. Physiol. Heart Circ. Physiol. 2006 291 : H748 55.
9. Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA 2003 100 : 4802 6.
10. van der Meer P, Lipsic E, Henning RH et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 2005 46 : 125 33.
11. Nishiya D, Omura T, Shimada K et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J. Pharmacol. Sci. 2006 101 : 31 9.
12. Tada H, Kagaya Y, Takeda M et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc. Res. 2006 71 : 466 77.
13. Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003 112 : 999 1007.
14. Rafiee P, Shi Y, Su J, Pritchard Jr. KA, Tweddell JS, Baker JE. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res. Cardiol. 2005 100 : 187 97.
15. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion: A target for cardioprotection. Cardiovasc. Res. 2004 61 : 372 85.
16. Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol. Biochem. 2007 20 : 1 22.
17. Juhaszova M, Zorov DB, Kim SH et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 2004 113 : 1535 49.
18. Bijur GN, Jope RS. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J. Neurochem. 2003 87 : 1427 35.
19. ATP channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2002 283 : H440 7.
20. ATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism. Cardiovasc. Res. 2006 70 : 374 83.
21. ATP channels attenuates the ouabain-induced calcium overload in mitochondria. Circ. Res. 2001 89 : 856 8.
22. 2+ overload with accompanying depolarization of the mitochondrial membrane in the heart. Naunyn Schmiedebergs Arch. Pharmacol. 2004 369 : 192 7.
23. Olea FD, Vera Janavel G, De Lorenzi A et al. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J. Cardiovasc. Pharmacol. 2006 47 : 736 41.
24. Dorn GW Souroujon MC, Liron T et al. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc. Natl Acad. Sci. USA 1999 96 : 12 798 803.
25. Chen CH, Gray MO, Mochly-Rosen D. Cardioprotection from ischemia by a brief exposure to physiological levels of ethanol: Role of epsilon protein kinase C. Proc. Natl Acad. Sci. USA 1999 96 : 12 784 9.
26. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J. Biol. Chem. 2001 276 : 30 724 8.
27. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2005 288 : H971 6.
28. Förster K, Paul I, Solenkova N et al. NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res. Cardiol. 2006 101 : 319 26.
29. Park SS, Zhao H, Jang Y, Mueller RA, Xu Z. N6-(3-iodobenzyl)-adenosine- 5′-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta. J. Pharmacol. Exp. Ther. 2006 318 : 124 31.
30. Park SS, Zhao H, Mueller RA, Xu Z. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J. Mol. Cell. Cardiol. 2006 40 : 708 16.
31. Shi Y, Rafiee P, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol. 2004 99 : 173 82.
32. + pump inhibition and metabolic inhibition in cultured neonatal rat cardiac myocytes. J. Clin. Invest. 1989 83 : 1876 87.
33. Rodriguez-Sinovas A, Boengler K, Cabestrero A et al. Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection. Circ. Res. 2006 99 : 93 101.